Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
25/08/2026 12:44
BRIEF-Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026 Aug 25 (Reuters) - Sagimet Biosciences Inc. SGMT.O:
SAGIMET BIOSCIENCES ADVANCES AURORA U.S. PHASE 3 TRIAL OF DENIFANSTAT IN ACNE TOWARD PATIENT ENROLLMENT IN Q4 2026
SAGIMET BIOSCIENCES - PATIENT SCREENING FOR AURORA PHASE 3 TRIAL TO BEGIN IN OCTOBER 2026
SAGIMET BIOSCIENCES - ALL CLINICAL TRIAL SITES IDENTIFIED AND CRO RETAINED FOR AURORA PHASE 3 TRIAL
SAGIMET BIOSCIENCES INC.: ANTICIPATE SUBMITTING AN NDA UPON COMPLETION OF 12-WEEK PHASE OF STUDY
Source text: ID:nGNX5QyJl6
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage